Europe led the biosimilar market since 2006 with clear regulations and fast adoption. The U.S. lagged due to legal and regulatory barriers - until 2024, when the FDA removed key roadblocks. Now, the U.S. is racing to catch up, with biosimilars poised to save billions in healthcare costs.
Read More
Generic drugs saved the U.S. healthcare system $467 billion in 2024 and $3.4 trillion over the past decade. Learn how these affordable alternatives cut costs, who benefits most, and why more savings are still possible.
Read More